首页>
外国专利>
EXTRACELLULAR N-TERMINAL DOMAIN VARIANT OF SULFATED CHEMOKINE RECEPTOR 3, AND COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION COMPRISING SAME
EXTRACELLULAR N-TERMINAL DOMAIN VARIANT OF SULFATED CHEMOKINE RECEPTOR 3, AND COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION COMPRISING SAME
展开▼
机译：硫酸化趋化因子受体3的胞外N末端域变体，以及用于预防或治疗相同的黄斑变性的组合物
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to an extracellular N-terminal domain variant of a sulfated chemokine receptor 3, and a composition for preventing or treating mascular degeneration comprising the same. A sulfated chemokine receptor 3 (S-CCR3) peptide of the present invention has been shown to have an effect of inhibiting a mascular degeneration pathological phenomenon in which retinal pigment epithelium degeneration occurs due to neovascularization, that is, an effect of inhibiting neovascularization and repair of retinal pigmented epithelial cells. A CCR3 monoclonal antibody therapeutic agent is difficult to crystallize the entire structure of CCR3 (including a 7 membrane spanning region), and thus an antibody therapeutic agent is not yet released unlike other types of receptors. However, according to the present invention, it is believed that the present invention has much better economical efficiency than a monoclonal antibody, and has little immune resistance and toxicity as a natural peptide, thereby having strong competitive competitiveness for new medicine development in the market of treatment of macular degeneration diseases.;COPYRIGHT KIPO 2018
展开▼
